文献

J-GLOBAL ID：202002259914638424   整理番号：20A2716105

心不全におけるナトリウム-グルコース共輸送体2阻害剤に関する欧州心臓病学会の心不全協会【JST・京大機械翻訳】

Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure

著者 (44件)： Seferovic Petar M. (Faculty of Medicine, University of Belgrade, Belgrade, Serbia) ,  Seferovic Petar M. (Serbian Academy of Sciences and Arts, Belgrade, Serbia) ,  Fragasso Gabriele (Heart Failure Unit, Clinical Cardiology, University Hospital San Raffaele, Milan, Italy) ,  Petrie Mark (Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK) ,  Mullens Wilfried (Faculty of Medicine and Life Sciences, BIOMED - Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium) ,  Mullens Wilfried (Department of Cardiology, Ziekenhuis Oost, Genk, Belgium) ,  Ferrari Roberto (Department of Cardiology and LTTA Centre, University Hospital of Ferrara and Maria Cecilia Hospital, GVM Care and Research, ES Health Science Foundation, Cotignola, Italy) ,  Thum Thomas (Hannover Medical School, Institute of Molecular and Translational Therapeutic Strategies, Hannover, Germany) ,  Bauersachs Johann (Department of Cardiology and Angiology, Medical School Hannover, Hannover, Germany) ,  Anker Stefan D. (Department of Cardiology (CVK), Berlin Institute of Health Centre for Regenerative Therapies (BCRT), Berlin, Germany) ,  Anker Stefan D. (German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charite Universitaetsmedizin Berlin, Berlin, Germany) ,  Ray Robin (Basildon and Thurrock University Hospitals NHS Foundation Trust, Basildon, UK) ,  Cavusoglu Yuksel (Department of Cardiology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey) ,  Polovina Marija (Faculty of Medicine, University of Belgrade, Belgrade, Serbia) ,  Polovina Marija (Department of Cardiology, Clinical Centre of Serbia, Belgrade, Serbia) ,  Metra Marco (Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy) ,  Ambrosio Giuseppe (Division of Cardiology, University of Perugia, Perugia, Italy) ,  Prasad Krishna (United Kingdom Medicines and Healthcare Products Regulatory Agency, London, UK) ,  Seferovic Jelena (Faculty of Medicine, University of Belgrade, Belgrade, Serbia) ,  Seferovic Jelena (Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre, Belgrade, Serbia) ,  Jhund Pardeep S. (British Heart Foundation, Cardiovascular Research Centre, University of Glasgow, Glasgow, UK) ,  Dattilo Giuseppe (Department of Clinical and Experimental Medicine, University of Messina, Cardiology Unit, Messina, Italy) ,  Celutkiene Jelena (Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania) ,  Piepoli Massimo (Heart Failure Unit, Cardiology, G. da Saliceto Hospital, Piacenza, Italy) ,  Moura Brenda (Hospital das Forcas Armadas and Cintesis- Faculdade de Medicina da Universidade do Porto, Porto, Portugal) ,  Chioncel Ovidiu (University of Medicine Carol Davila, Bucharest, Romania) ,  Chioncel Ovidiu (Emergency Institute for Cardiovascular Diseases ‘Prof. C.C. Iliescu’, Bucharest, Romania) ,  Ben Gal Tuvia (Department of Cardiology, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel) ,  Heymans Stephane (Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands) ,  Jaarsma Tiny (Department of Social and Welfare Studies, Faculty of Health Science, Linkoping University, Linkoping, Sweden) ,  Hill Loreena (School of Nursing and Midwifery, Queen’s University Belfast, Belfast, UK) ,  Lopatin Yuri (Volgograd State Medical University, Regional Cardiology Centre Volgograd, Volgograd, Russian Federation) ,  Lyon Alexander R. (National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital, London, UK) ,  Ponikowski Piotr (Centre for Heart Diseases, Faculty of Health Sciences, Wroclaw Medical University, Wroclaw, Poland) ,  Lainscak Mitja (Department of Internal Medicine, and Department of Research and Education, General Hospital Murska Sobota, Murska Sobota, Slovenia) ,  Lainscak Mitja (Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia) ,  Jankowska Ewa (Centre for Heart Diseases, Faculty of Health Sciences, Wroclaw Medical University, Wroclaw, Poland) ,  Mueller Christian (Department of Cardiology, Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland) ,  Cosentino Francesco (Cardiology Unit, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden) ,  Lund Lars H. (Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden) ,  Filippatos Gerasimos S. (National and Kapodistrian University of Athens, School of Medicine, University Hospital Attikon, Athens, Greece) ,  Ruschitzka Frank (Department of Cardiology, University Heart Center, Zuerich, Switzerland) ,  Coats Andrew J.S. (Pharmacology, Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy) ,  Rosano Giuseppe M.C. (Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy)
資料名： European Journal of Heart Failure  (European Journal of Heart Failure)
巻： 22  号： 11  ページ： 1984-1986  発行年： 2020年 
JST資料番号： W2568A  ISSN： 1388-9842  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： 欧州心臓病学会(ESC)の心不全協会(HFA)は,心不全(HF)におけるナトリウム-グルコース共輸送体2(SGLT2)阻害剤の役割に関する位置論文を最近発行した。現在の文書は,新しい臨床試験証拠に基づき,位置論文の更新を提供する。したがって,以下の推奨事項を示した:Canagliflozin,dapagliflozin empagliflozin,またはertugliflozinを,2型糖尿病患者のHF入院の予防のために推奨し,心血管疾患または高心血管リスクを確立した。HFの症候性患者におけるHF入院と心血管死亡の複合リスクを低減するため,および2型糖尿病の存在に関係なく,ガイドライン指向の医療療法を受けている駆出率を減じるように,Dapagliflozinまたはempagliflozinが推奨されている。Copyright 2020 Wiley Publishing Japan K.K. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： *心不全 ,  心血管疾患 ,  臨床試験 ,  ヨーロッパ ,  循環系 ,  2型糖尿病
準シソーラス用語： *心臓病学 ,  駆出率 ,  ナトリウム-グルコース輸送体2 ,  腎機能 ,  心血管リスク ,  心血管死 , 【Automatic Indexing@JST】

著者キーワード (5件)： 心不全 ,  ナトリウム-グルコース共輸送体2阻害剤 ,  2型糖尿病 ,  心血管転帰 ,  腎機能

分類 (2件)： 糖質代謝作用薬の臨床への応用  (GW13030B) ,  代謝異常・栄養性疾患の治療  (GD05030F)

タイトルに関連する用語 (9件)： 心不全 ,  ナトリウム ,  グルコース ,  共輸送体 ,  阻害剤 ,  欧州 ,  心臓病 ,  学会 ,  協会